Metamizolnatrij Hidrat Bausch Health

Metamizole Sodium Monohydrate, the active ingredient in Metamizolnatrij Hidrat, is a pyrazolone derivative presented as an oral dosage form for oral use. It is employed to relieve pain and reduce fever in adult patients.

GNH USA supplies Metamizolnatrij Hidrat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches and regulatory compliance for global distribution. The company adheres to EU GMP standards and provides full documentation for importers, with customer support that includes technical assistance and timely shipment tracking.

Metamizole Sodium Monohydrate is used for analgesic and antipyretic therapy in conditions requiring pain relief or fever reduction.

- Pain: provides effective analgesia for moderate to severe acute pain. - Fever: reduces elevated body temperature in febrile states. - Post‑operative pain: helps control pain after surgical procedures. - Cancer‑related pain: may be used as part of multimodal analgesia for cancer patients.

Metamizole Sodium Monohydrate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Vomiting: occasional episodes. - Dizziness: transient light‑headedness. - Skin rash: mild erythema. - Hypotension: transient drop in blood pressure.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction of white blood cells. - Anaphylaxis: life‑threatening allergic reaction. - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder. - Hepatotoxicity: liver enzyme elevation or injury. - Blood dyscrasias: including thrombocytopenia or hemolytic anemia.

When prescribing Metamizole Sodium Monohydrate, clinicians should consider several safety precautions. - Renal impairment: use with caution in patients with reduced kidney function. - Hepatic disease: monitor liver function tests during therapy. - History of blood disorders: avoid in patients with prior agranulocytosis or leukopenia. - Concomitant immunosuppressants: increase risk of infection. - Elderly patients: start at lower doses and monitor for adverse effects. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Metamizole Sodium Monohydrate can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Methotrexate: enhanced toxicity due to reduced renal clearance. - Cyclosporine: possible nephrotoxicity augmentation. - Lithium: may increase serum lithium levels. - ACE inhibitors: risk of additive hypotension.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation. - SSRIs or SNRIs: potential for increased bleeding. - Diuretics: may enhance hypotensive effect. - Antihypertensives: may require dose adjustment. - Oral contraceptives: possible reduction in efficacy.